The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases
- 1 February 2017
- journal article
- review article
- Published by Elsevier BV in Clinical Immunology
- Vol. 175, 10-15
- https://doi.org/10.1016/j.clim.2016.11.008
Abstract
No abstract availableKeywords
Funding Information
- NIH (UM1-AI110557, UM1-AI110557, R01-NS080821)
- Novartis
- University of Michigan
This publication has 57 references indexed in Scilit:
- Cytokine inhibition as a strategy for treating systemic lupus erythematosusClinical Immunology, 2013
- The selective sphingosine 1‐phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species‐specific effects on heart rateBritish Journal of Pharmacology, 2012
- Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple SclerosisPharmaceuticals, 2012
- Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implicationsCurrent Opinion in Neurology, 2011
- Mechanisms of neuronal dysfunction and degeneration in multiple sclerosisProgress in Neurobiology, 2011
- Abnormalities of T cell signaling in systemic lupus erythematosusArthritis Research & Therapy, 2011
- Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosisProceedings of the National Academy of Sciences of the United States of America, 2008
- Involvement of Sphingosine-1-Phosphate in Glutamate Secretion in Hippocampal NeuronsMolecular and Cellular Biology, 2007
- Intracellular sphingosine 1‐phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neuronsJournal Of Physiology-London, 2006
- Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p1 in neurogenesis and s1p1–3 in angiogenesisFEBS Letters, 2002